These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15645680)

  • 1. Methods for validation of hepatitis B virus inactivation.
    Gerlich WH; Glebe D
    Dev Biol (Basel); 2004; 118():113-22. PubMed ID: 15645680
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantitative NAT for pathogen inactivation verification.
    McKenney K; Gillmeister L; Marlowe K; Armistead D; Burgess W; Drohan W
    Dev Biol (Basel); 2004; 118():81-8. PubMed ID: 15645676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virology of hepatitis B and C viruses and antiviral targets.
    Pawlotsky JM
    J Hepatol; 2006; 44(1 Suppl):S10-3. PubMed ID: 16338022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theoretical considerations on viral inactivation or elimination.
    Willkommen H; Löwer J
    Dev Biol Stand; 1993; 81():109-16. PubMed ID: 8174793
    [No Abstract]   [Full Text] [Related]  

  • 5. Robustness studies on virus inactivation: definition of parameters and their generic use.
    Dichtelmüller H
    Dev Biol (Basel); 2004; 118():125-7. PubMed ID: 15645681
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatitis B virus polymerase chain reaction--a possible alternative method to the in vivo assay using chimpanzees.
    Chudy M; Weeke-Lüttmann M; Löwer J
    Dev Biol Stand; 1996; 86():328. PubMed ID: 8785968
    [No Abstract]   [Full Text] [Related]  

  • 7. Donor screening for hepatitis B virus infection in a cell and tissue bank.
    Solves P; Mirabet V; Alvarez M; Vila E; Quiles F; Villalba JV; Montoro JA; Soler MA; Roig RJ
    Transpl Infect Dis; 2008 Dec; 10(6):391-5. PubMed ID: 18665905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1991 Jul; 19(3):247-51. PubMed ID: 1954007
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
    Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
    Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualification of virus/cell systems for their intended use.
    Gröner A
    Dev Biol (Basel); 2004; 118():55-63. PubMed ID: 15645673
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness of various minipool nucleic acid test systems for hepatitis B virus detection in blood donors.
    Grabarczyk P; Letowska M; Kopacz A; Liszewski G; Sulkowska E; Brojer E
    Transfusion; 2009 Jul; 49(7):1494-5. PubMed ID: 19602212
    [No Abstract]   [Full Text] [Related]  

  • 12. HBV-DNA levels in HBsAg-positive blood donors and its relationship with liver histology.
    Nabuco LC; Villela-Nogueira CA; Perez RM; Ceci L; Pannain VL; Nogueira CM; Segadas-Soares JA; Coelho HS
    J Clin Gastroenterol; 2007 Feb; 41(2):194-8. PubMed ID: 17245219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area.
    Hui CK; Sun J; Au WY; Lie AK; Yueng YH; Zhang HY; Lee NP; Hou JL; Liang R; Lau GK
    J Hepatol; 2005 Jun; 42(6):813-9. PubMed ID: 15885351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand.
    Nantachit N; Thaikruea L; Thongsawat S; Leetrakool N; Fongsatikul L; Sompan P; Fong YL; Nichols D; Ziermann R; Ness P; Nelson KE
    Transfusion; 2007 Oct; 47(10):1803-8. PubMed ID: 17880604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of serologic marker screening in identifying hepatitis B virus infection in organ, tissue, and cell donors.
    Challine D; Chevaliez S; Pawlotsky JM
    Gastroenterology; 2008 Oct; 135(4):1185-91. PubMed ID: 18694749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of bacteriophages as surrogates for mammalian viruses.
    McAlister M; Aranha H; Larson R
    Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus infection and transfusion medicine: science and the occult.
    Hollinger FB
    Transfusion; 2008 May; 48(5):1001-26. PubMed ID: 18454738
    [No Abstract]   [Full Text] [Related]  

  • 18. [Evaluation of susceptibility of tupaia to hepatitis B virus with cyclosporin A].
    Luo HY; Yang X; Su XS
    Hunan Yi Ke Da Xue Xue Bao; 2000 Jun; 25(3):297-8. PubMed ID: 12212175
    [No Abstract]   [Full Text] [Related]  

  • 19. Lack of correlation between hepatitis B surface antigen and hepatitis B virus DNA levels in blood donors.
    Allain JP; Sarkodie F; Candotti D; Opare-Sem O
    Transfusion; 2005 Jun; 45(6):1039-40. PubMed ID: 15935007
    [No Abstract]   [Full Text] [Related]  

  • 20. Epidemiology of blood donors in Japan, positive for hepatitis B virus and hepatitis C virus by nucleic acid amplification testing.
    Murokawa H; Yoshikawa A; Ohnuma H; Iwata A; Katoh N; Miyamoto M; Mine H; Emura H; Tadokoro K;
    Vox Sang; 2005 Jan; 88(1):10-6. PubMed ID: 15663717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.